Obinutuzumab (Gazyva) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the trea™ent of chronic lymphocytic leukemia and follicular lymphoma. It binds to a unique conformation epitope on CD20 protein, which partially overlaps with the section recognized by rituximab. When Obinutuzumab binds to CD20 on B cells, it makes these cells to be destroyed by the adaptive immune system. GenScript MonoRab™ Anti-Obinutuzumab Antibody (8G12), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Obinutuzumab.